Compounds and methods for treating an epileptic disorder

1. A method of treating an epilepsy disorder, said method comprising administering to a subject having the disorder, a therapeutically effective amount of clemizole, or a pharmaceutically acceptable salt thereof, wherein the clemizole is not combined with another active compound capable of treating said epilepsy disorder, and further wherein the pharmaceutically acceptable salt is clemizole hydrochloride, clemizole hydrobromide, clemizole hydroiodide, clemizole sulfates, clemizole sulfonates, clemizole phosphates, clemizole monohydrogenphosphates, clemizole dihydrogenphosphates, clemizole nitrates, clemizole carbonates, clemizole monohydrogencarbonates, clemizole maleates, clemizole undecylates, clemizole malates, clemizole acetates, clemizole citrates, clemizole fumarates, clemizole propionates, clemizole isobutyrates, clemizole malonates, clemizole suberates, clemizole lactates, clemizole mandelates, clemizole phthalates, clemizole oxalates, clemizole benzenesulfonates, clemizole p-tolylsulfonates, clemizole methanesulfonates, clemizole tartrates, clemizole succinates, clemizole benzoates, clemizole penicillin, clemizole salts with amino acids or a quaternary ammonium salt of clemizole.

2. The method of claim 1 , wherein said epilepsy disorder is Dravet Syndrome, Lennox-Gastaut Syndrome, infantile spasm, or Ohtahara Syndrome.

3. The method of claim 1 , wherein said epilepsy disorder is Dravet Syndrome.

4. The method of claim 1 , wherein said epilepsy disorder is a pediatric epilepsy disorder.

5. The method of claim 1 , wherein said administration of clemizole or a pharmaceutically acceptable salt thereof inhibits compulsive behaviors or electrographic seizures in an epilepsy subject, an Alzheimer's disease subject, an autism subject, or a Parkinson's disease subject.

6. The method of claim 1 , wherein said administration of clemizole or a pharmaceutically acceptable salt thereof reduces the incidence of unprovoked seizures in said subject when compared to the absence of clemizole, said clemizole analog, or said pharmaceutically acceptable salt thereof.

7. The method of claim 1 , wherein said administration of clemizole or a pharmaceutically acceptable salt thereof reduces or prevents myoclonus seizures or status epilepticus in said subject when compared to the absence of clemizole, said clemizole analog, or said pharmaceutically acceptable salt thereof.

8. The method of claim 1 , wherein said subject has a ketogenic diet.

9. The method of claim 1 , wherein said clemizole or a pharmaceutically acceptable salt thereof is administered to said subject at an amount of about 0.1 mg to about 1000 mg per kg body weight.

10. The method of claim 9 , wherein said clemizole or a pharmaceutically acceptable salt thereof is administered to said subject in a daily dose of about 0.1 mg to about 1000 mg per kg body weight to said subject.

11. The method of claim 1 , wherein said pharmaceutically acceptable salt is clemizole HCl.

12. The method of claim 1 , wherein said clemizole or a pharmaceutically acceptable salt thereof comprises a pharmaceutical composition.

13. The method of claim 12 , wherein said pharmaceutical composition further comprises a pharmaceutically acceptable excipient.

14. The method of claim 12 , wherein said pharmaceutical composition comprises a therapeutically effective amount of said clemizole or a pharmaceutically acceptable salt thereof.

15. The method of claim 14 , wherein said pharmaceutically acceptable salt is clemizole HCl.